Tambocor Dosage/Direction for Use

For Oral Use only.
Adults: Supraventricular arrhythmias: The recommended starting dosage is 50 mg twice daily and most patients will be controlled at this dose. If required, the dose may be increased to a maximum of 300 mg daily.
Ventricular arrhythmias: The recommended starting dosage is 100 mg twice daily. The maximum daily dose is 400 mg and this is normally reserved for patients of large build or where rapid control of the arrhythmia is required. After 3-5 days, it is recommended that the dosage be progressively adjusted to the lowest level which maintains control of the arrhythmia. It may be possible to reduce dosage during long-term treatment.
Children: Tambocor Tablet 100 mg is not recommended in children under 12, as there is insufficient evidence of its use in this age group.
Elderly patients: The rate of Flecainide elimination from plasma may be reduced in elderly people. This should be taken into consideration when making dose adjustments.
Plasma Levels: Based on PVC suppression, it appears that plasma levels of 200-1000 ng/mL may be needed to obtain the maximum therapeutic effect. Plasma levels above 700-1000 ng/mL are associated with increased likelihood of adverse experiences.
Dosage in Impaired Renal Function: In patients with significant renal impairment (creatinine clearance of 35 mL/min/1.73 m² or less), the maximum initial dosage should be 100 mg daily (or 50 mg twice daily). When used in such patients, frequent plasma level monitoring is strongly recommended.